Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

NFkB decoy oligonucleotide moves to phase III study in atopic dermatitis

Aug. 26, 2014

Auxilium and BioSpecifics report positive data from phase IIa trial of Xiaflex

Aug. 22, 2014

Lilly's ixekizumab superior to etanercept in phase III plaque psoriasis trials

Aug. 22, 2014

Covance to conduct phase I/II study of AM-1030 in atopic dermatitis

Aug. 20, 2014

Phase I study of Cellceutix's Prurisol meets primary endpoint

Aug. 13, 2014

Organogenesis wins U.S. Department of Veteran Affairs contract for Apligraf

Aug. 8, 2014

Rogne Bioscience in-licenses anti-inflammatory peptide for development as psoriasis drug

Aug. 6, 2014

Dignity Sciences completes phase I trial of oral DS-107G

Aug. 5, 2014

Amniox Medical initiates clinical trial of placenta-derived diabetic foot ulcer therapy

Aug. 4, 2014

Immune Pharmaceuticals initiates phase II trial of bertilimumab in bullous pemphigoid

July 31, 2014

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.